Biran N, Zolotov E, Vesole D, Parmar H, Phull P, Doucette K, Roney P, Ahn J, Feinman R, Zenreich J, Anand P, Pace M, Pia AD, DeAgresta B, Biamonte L, Aleman A, Rutanen E, Chappell A, Kumka S, Siegel DS. A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma. haematol [Internet]. 2025Oct.1 [cited 2026Feb.8];110(10):2493-7. Available from: https://haematologica.org/article/view/12009